search
Back to results

Computed Tomogram Myocardial Thickness Map Guided pulmOnary Vein iSolaTion vs. Empirical Pulmonary Vein Isolation in Cryoballoon Ablation for Paroxysmal Atrial Fibrillation (UTMOST AF II)

Primary Purpose

Paroxysmal Atrial Fibrillation

Status
Recruiting
Phase
Not Applicable
Locations
Korea, Republic of
Study Type
Interventional
Intervention
Unipolar voltage subtraction map guided PV isolation group
CT myocardial thickness map guided PV isolation group
Empirical PV isolation group
Sponsored by
Yonsei University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Paroxysmal Atrial Fibrillation focused on measuring Atrial fibrillation, Pulmonary vein isolation

Eligibility Criteria

20 Years - 80 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Patient with paroxysmal atrial fibrillation who is scheduled for ablation procedure and ≥20 and ≤80 years of age
  2. Left atrium size < 50mm
  3. paroxysmal atrial fibrillation that is recurrence during antiarrhythmic drug treatment or is not able to use an antiarrhythmic drug.
  4. Patient who is indicated for anticoagulation therapy (for prevention of cerebral infarction)

Exclusion Criteria:

  1. Patients with persistent or permanent atrial fibrillation
  2. Atrial fibrillation associated with severe cardiac malformation or a structural heart disease that is hemodynamically affected
  3. Patients with severe renal impairment or CT imaging difficulty using contrast media
  4. Patients with a past history of radiofrequency ablation for atrial fibrillation or other cardiac surgery
  5. Patients with active internal bleeding
  6. Patients with contraindications for anticoagulation therapy(for prevention of cerebral infarction) and antiarrhythmic drugs
  7. Patients with valvular atrial fibrillation (mitral stenosis >grade 2, mechanical valve, mitral valvuloplasty)
  8. Patients with a severe comorbid disease
  9. Expected survival < 1 year
  10. Drug addicts or alcoholics
  11. Patients who cannot read the consent form (illiterates, foreigners, etc.)
  12. Other patients who are judged by the principal or sub-investigator to be ineligible for participation in this clinical study

Sites / Locations

  • Severance Cardiovascular Hospital, Yonsei University Health SystemRecruiting

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Experimental

Experimental

Active Comparator

Arm Label

Unipolar voltage subtraction map guided PV isolation group

CT myocardial thickness map guided PV isolation group

Empirical PV isolation group

Arm Description

Pulmonary vein isolation will be performed using a radiofrequency catheter Esophageal temperature will be monitored to prevent esophageal injury Mapping of echocardiographic unipolar voltage subtraction after atrial septal puncture the electrode map data is transferred to the core lab by network to calculate the unipolar voltage subtraction color map (within 10 minutes) Increase radiofrequency ablation time by 2 to 5 seconds in areas with high potential in unipolar voltage subtraction color map Decrease radiofrequency ablation time by 2 to 5 seconds in areas with low potential in unipolar voltage subtraction color map Evaluation of success rate and time of pulmonary vein isolation after bilateral pulmonary vein primary columnar resection Evaluate time to complete isolation after additional ablation Evaluation of Procedure and Ablation time, and perfusion saline dose Rhythm follow-up after the procedure in accordance with the study design.

Pulmonary vein isolation will be performed using a radiofrequency catheter Esophageal temperature will be monitored to prevent esophageal injury. Prepared myocardial thickness map with CT DICOM images conducted prior to procedure. Increase radiofrequency ablation time by 2 to 5 seconds in thick areas in CT myocardial thickness map Decrease radiofrequency ablation time by 2 to 5 seconds in thin areas in CT myocardial thickness map Evaluation of success rate and time of pulmonary vein isolation after bilateral pulmonary vein primary columnar resection Evaluate time to complete isolation after additional ablation Evaluation of Procedure time, Ablation time, and perfusion saline dose Rhythm follow-up will be performed after the procedure in accordance with the aforementioned study design.

Pulmonary vein isolation will be performed using a radiofrequency catheter Esophageal temperature will be monitored to prevent esophageal injury. The procedure is performed by adjusting radiofrequency energy according to the traditional method and experience of the practitioner. Evaluation of success rate and time of pulmonary vein isolation after bilateral pulmonary vein primary columnar resection Evaluate time to complete isolation after additional ablation Evaluation of Procedure time, Ablation time, and perfusion saline dose Rhythm follow-up will be performed after the procedure in accordance with the aforementioned study design.

Outcomes

Primary Outcome Measures

Safety evaluation: Procedure-related cardiac complication rate
including open cardiac surgery, cerebral infarction, pericardial effusion or cardiac tamponade, hematoma in the inguinal puncture site and vascular complications within 30 days post procedure.
Efficacy evaluation: clinical recurrence rate
Defined as atrial fibrillation or atrial tachycardia > 30 sec after 3 months within 1 year; based on the 2012 ACC/AHA/HRS guidelines, 24-hour Holter ECG monitoring will be performed at 2 month and every 6 months, and ECG and monitoring with a Holter or an event recorder will be performed at any time if the patient complains of symptoms
Efficacy evaluation: Major cardiovascular event rate
death, myocardial infarction, coronary angioplasty, and re-hospitalization for arrhythmia and heart failure
Efficacy evaluation: Major cardiovascular event rate
death, myocardial infarction, coronary angioplasty, and re-hospitalization for arrhythmia and heart failure

Secondary Outcome Measures

Comparison of procedure time
Comparison of ablation time
Comparison of hospitalization period
Comparison of anti-arrhythmic drug or anticoagulation therapy related complication rate
Comparison of anti-arrhythmic drug or anticoagulation therapy related complication rate
Comparison of anti-arrhythmic drug or anticoagulation therapy related complication rate
Comparison of anti-arrhythmic drug or anticoagulation therapy related complication rate
Comparison of anti-arrhythmic drug or anticoagulation therapy related complication rate
Comparison of anti-arrhythmic drug or anticoagulation therapy related complication rate
Comparison of anti-arrhythmic drug or anticoagulation therapy related complication rate
Comparison of re-hospitalization rate after the procedure
Comparison of re-hospitalization rate after the procedure
Comparison of re-hospitalization rate after the procedure
Comparison of re-hospitalization rate after the procedure
Comparison of re-hospitalization rate and number of electrical cardioversion after the procedure
Comparison of re-hospitalization rate after the procedure
Comparison of re-hospitalization rate after the procedure
Comparison of number of electrical cardioversion after the procedure
Comparison of number of electrical cardioversion after the procedure
Comparison of number of electrical cardioversion after the procedure
Comparison of number of electrical cardioversion after the procedure
Comparison of number of electrical cardioversion after the procedure
Comparison of number of electrical cardioversion after the procedure
Comparison of number of electrical cardioversion after the procedure

Full Information

First Posted
April 8, 2019
Last Updated
January 11, 2023
Sponsor
Yonsei University
search

1. Study Identification

Unique Protocol Identification Number
NCT03912324
Brief Title
Computed Tomogram Myocardial Thickness Map Guided pulmOnary Vein iSolaTion vs. Empirical Pulmonary Vein Isolation in Cryoballoon Ablation for Paroxysmal Atrial Fibrillation (UTMOST AF II)
Official Title
Computed Tomogram Myocardial Thickness Map Guided pulmOnary Vein iSolaTion vs. Empirical Pulmonary Vein Isolation in Cryoballoon Ablation for Paroxysmal Atrial Fibrillation (UTMOST AF II)
Study Type
Interventional

2. Study Status

Record Verification Date
January 2023
Overall Recruitment Status
Recruiting
Study Start Date
October 6, 2021 (Actual)
Primary Completion Date
April 2024 (Anticipated)
Study Completion Date
April 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Yonsei University

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
New parameters or methods, such as ablation index, have been developed for the quantification of high-frequency energy used in pulmonary vein isolation, but there is no known method for atrial fibrillation considering individual differences in atrial tissue. The atrium is only 1/3 of the thickness of the ventricle and is thinner in women and older than men or young people. The aim of this study was to evaluate the efficacy and safety of radiofrequency energy therapy using atrial individual differences. In order to reflect the thickness of the atrium, we will use the unipolar and bipolar maps and the myocardial thickness map using computed tomography (CT) images. To evaluate the efficacy and safety of energy titration therapy by random assignment of high frequency energy therapy group, CT image application high frequency energy therapy group, and existing empirical high frequency therapy group.
Detailed Description
A. Study design Prospective randomization (Unipolar voltage subtraction map guided PV(pulmonary vein) isolation group vs. CT myocardial thickness map guided PV isolation group vs. Empirical PV isolation group ) Target number of subjects: 480 (160 per group) Rhythm FU : 2012 ACC/AHA/ESC guidelines (Holter monitoring at the baseline, 2 month, and thereafter every 6 months; ECG if the patient has any symptom) Anticoagulant therapy followed by 2014 ACC/AHA/ESC guidelines All complications in each group will be evaluated including the re-hospitalization rate, major cardiovascular event, and mortality rate. B. Progress and rhythm/ECG follow-up To be performed in accordance with the 2012 ACC/AHA/HRS guidelines for AF management Follow-up at 1 weeks, 3 months, and thereafter every 6-month after procedure. Rhythm control at 3 months, and thereafter every 6-month follow-up with Holter If the patient complains of symptoms, ECG will be performed at any time, and rhythm follow-up will be carried out with a Holter or event recorder. C. Follow-up All the patients will be followed-up at 1, 3, 6 months, and thereafter every 6 months. If the patient shows any symptom within the clinical study period, patient will visit the outpatient clinic. ECG will be performed at every outpatient visits, and 24-hour Holter or event recording will be performed every 6 months for 2 years, and every year after 2 years (2012 Heart Rhythm Society/EHRA/European Cardiac Arrhythmia Society Expert Consensus Statement guidelines). If atrial fibrillation or atrial tachycardia lasting more than 30 seconds is observed in 12-lead ECG or Holter, it will be evaluated as recurrence. Recurrence within 3 months after the procedure will be classified as early recurrence, and that after 3 months will be classified as clinical recurrence.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Paroxysmal Atrial Fibrillation
Keywords
Atrial fibrillation, Pulmonary vein isolation

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
220 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Unipolar voltage subtraction map guided PV isolation group
Arm Type
Experimental
Arm Description
Pulmonary vein isolation will be performed using a radiofrequency catheter Esophageal temperature will be monitored to prevent esophageal injury Mapping of echocardiographic unipolar voltage subtraction after atrial septal puncture the electrode map data is transferred to the core lab by network to calculate the unipolar voltage subtraction color map (within 10 minutes) Increase radiofrequency ablation time by 2 to 5 seconds in areas with high potential in unipolar voltage subtraction color map Decrease radiofrequency ablation time by 2 to 5 seconds in areas with low potential in unipolar voltage subtraction color map Evaluation of success rate and time of pulmonary vein isolation after bilateral pulmonary vein primary columnar resection Evaluate time to complete isolation after additional ablation Evaluation of Procedure and Ablation time, and perfusion saline dose Rhythm follow-up after the procedure in accordance with the study design.
Arm Title
CT myocardial thickness map guided PV isolation group
Arm Type
Experimental
Arm Description
Pulmonary vein isolation will be performed using a radiofrequency catheter Esophageal temperature will be monitored to prevent esophageal injury. Prepared myocardial thickness map with CT DICOM images conducted prior to procedure. Increase radiofrequency ablation time by 2 to 5 seconds in thick areas in CT myocardial thickness map Decrease radiofrequency ablation time by 2 to 5 seconds in thin areas in CT myocardial thickness map Evaluation of success rate and time of pulmonary vein isolation after bilateral pulmonary vein primary columnar resection Evaluate time to complete isolation after additional ablation Evaluation of Procedure time, Ablation time, and perfusion saline dose Rhythm follow-up will be performed after the procedure in accordance with the aforementioned study design.
Arm Title
Empirical PV isolation group
Arm Type
Active Comparator
Arm Description
Pulmonary vein isolation will be performed using a radiofrequency catheter Esophageal temperature will be monitored to prevent esophageal injury. The procedure is performed by adjusting radiofrequency energy according to the traditional method and experience of the practitioner. Evaluation of success rate and time of pulmonary vein isolation after bilateral pulmonary vein primary columnar resection Evaluate time to complete isolation after additional ablation Evaluation of Procedure time, Ablation time, and perfusion saline dose Rhythm follow-up will be performed after the procedure in accordance with the aforementioned study design.
Intervention Type
Procedure
Intervention Name(s)
Unipolar voltage subtraction map guided PV isolation group
Intervention Description
Pulmonary vein isolation will be performed using a radiofrequency catheter Esophageal temperature will be monitored to prevent esophageal injury Mapping of echocardiographic unipolar voltage subtraction after atrial septal puncture the electrode map data is transferred to the core lab by network to calculate the unipolar voltage subtraction color map (within 10 minutes) Increase radiofrequency ablation time by 2 to 5 seconds in areas with high potential in unipolar voltage subtraction color map Decrease radiofrequency ablation time by 2 to 5 seconds in areas with low potential in unipolar voltage subtraction color map Evaluation of success rate and time of pulmonary vein isolation after bilateral pulmonary vein primary columnar resection Evaluate time to complete isolation after additional ablation Evaluation of Procedure and Ablation time, and perfusion saline dose Rhythm follow-up after the procedure in accordance with the study design.
Intervention Type
Procedure
Intervention Name(s)
CT myocardial thickness map guided PV isolation group
Intervention Description
Pulmonary vein isolation will be performed using a radiofrequency catheter Esophageal temperature will be monitored to prevent esophageal injury. Prepared myocardial thickness map with CT DICOM images conducted prior to procedure. Increase radiofrequency ablation time by 2 to 5 seconds in thick areas in CT myocardial thickness map Decrease radiofrequency ablation time by 2 to 5 seconds in thin areas in CT myocardial thickness map Evaluation of success rate and time of pulmonary vein isolation after bilateral pulmonary vein primary columnar resection Evaluate time to complete isolation after additional ablation Evaluation of Procedure time, Ablation time, and perfusion saline dose Rhythm follow-up will be performed after the procedure in accordance with the aforementioned study design.
Intervention Type
Procedure
Intervention Name(s)
Empirical PV isolation group
Intervention Description
Pulmonary vein isolation will be performed using a radiofrequency catheter Esophageal temperature will be monitored to prevent esophageal injury. The procedure is performed by adjusting radiofrequency energy according to the traditional method and experience of the practitioner. Evaluation of success rate and time of pulmonary vein isolation after bilateral pulmonary vein primary columnar resection Evaluate time to complete isolation after additional ablation Evaluation of Procedure time, Ablation time, and perfusion saline dose Rhythm follow-up will be performed after the procedure in accordance with the aforementioned study design.
Primary Outcome Measure Information:
Title
Safety evaluation: Procedure-related cardiac complication rate
Description
including open cardiac surgery, cerebral infarction, pericardial effusion or cardiac tamponade, hematoma in the inguinal puncture site and vascular complications within 30 days post procedure.
Time Frame
within 30 days post procedure
Title
Efficacy evaluation: clinical recurrence rate
Description
Defined as atrial fibrillation or atrial tachycardia > 30 sec after 3 months within 1 year; based on the 2012 ACC/AHA/HRS guidelines, 24-hour Holter ECG monitoring will be performed at 2 month and every 6 months, and ECG and monitoring with a Holter or an event recorder will be performed at any time if the patient complains of symptoms
Time Frame
Within 1 year after 3 months of procedure
Title
Efficacy evaluation: Major cardiovascular event rate
Description
death, myocardial infarction, coronary angioplasty, and re-hospitalization for arrhythmia and heart failure
Time Frame
immediate after procedure
Title
Efficacy evaluation: Major cardiovascular event rate
Description
death, myocardial infarction, coronary angioplasty, and re-hospitalization for arrhythmia and heart failure
Time Frame
12 months after procedure
Secondary Outcome Measure Information:
Title
Comparison of procedure time
Time Frame
immediate after procedure
Title
Comparison of ablation time
Time Frame
immediate after procedure
Title
Comparison of hospitalization period
Time Frame
immediate after procedure
Title
Comparison of anti-arrhythmic drug or anticoagulation therapy related complication rate
Time Frame
1 week after procedure
Title
Comparison of anti-arrhythmic drug or anticoagulation therapy related complication rate
Time Frame
3 months after procedure
Title
Comparison of anti-arrhythmic drug or anticoagulation therapy related complication rate
Time Frame
6 months after procedure
Title
Comparison of anti-arrhythmic drug or anticoagulation therapy related complication rate
Time Frame
12 months after procedure
Title
Comparison of anti-arrhythmic drug or anticoagulation therapy related complication rate
Time Frame
18 months after procedure
Title
Comparison of anti-arrhythmic drug or anticoagulation therapy related complication rate
Time Frame
24 months after procedure
Title
Comparison of anti-arrhythmic drug or anticoagulation therapy related complication rate
Time Frame
36 months after procedure
Title
Comparison of re-hospitalization rate after the procedure
Time Frame
1 week after procedure
Title
Comparison of re-hospitalization rate after the procedure
Time Frame
3 months after procedure
Title
Comparison of re-hospitalization rate after the procedure
Time Frame
6 months after procedure
Title
Comparison of re-hospitalization rate after the procedure
Time Frame
12 months after procedure
Title
Comparison of re-hospitalization rate and number of electrical cardioversion after the procedure
Time Frame
18 months after procedure
Title
Comparison of re-hospitalization rate after the procedure
Time Frame
24 months after procedure
Title
Comparison of re-hospitalization rate after the procedure
Time Frame
36 months after procedure
Title
Comparison of number of electrical cardioversion after the procedure
Time Frame
1 week months after procedure
Title
Comparison of number of electrical cardioversion after the procedure
Time Frame
3 months after procedure
Title
Comparison of number of electrical cardioversion after the procedure
Time Frame
6 after procedure
Title
Comparison of number of electrical cardioversion after the procedure
Time Frame
12 months after procedure
Title
Comparison of number of electrical cardioversion after the procedure
Time Frame
18 months after procedure
Title
Comparison of number of electrical cardioversion after the procedure
Time Frame
24 months after procedure
Title
Comparison of number of electrical cardioversion after the procedure
Time Frame
36 months after procedure

10. Eligibility

Sex
All
Minimum Age & Unit of Time
20 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patient with paroxysmal atrial fibrillation who is scheduled for ablation procedure and ≥20 and ≤80 years of age Left atrium size < 50mm paroxysmal atrial fibrillation that is recurrence during antiarrhythmic drug treatment or is not able to use an antiarrhythmic drug. Patient who is indicated for anticoagulation therapy (for prevention of cerebral infarction) Exclusion Criteria: Patients with persistent or permanent atrial fibrillation Atrial fibrillation associated with severe cardiac malformation or a structural heart disease that is hemodynamically affected Patients with severe renal impairment or CT imaging difficulty using contrast media Patients with a past history of radiofrequency ablation for atrial fibrillation or other cardiac surgery Patients with active internal bleeding Patients with contraindications for anticoagulation therapy(for prevention of cerebral infarction) and antiarrhythmic drugs Patients with valvular atrial fibrillation (mitral stenosis >grade 2, mechanical valve, mitral valvuloplasty) Patients with a severe comorbid disease Expected survival < 1 year Drug addicts or alcoholics Patients who cannot read the consent form (illiterates, foreigners, etc.) Other patients who are judged by the principal or sub-investigator to be ineligible for participation in this clinical study
Facility Information:
Facility Name
Severance Cardiovascular Hospital, Yonsei University Health System
City
Seoul
ZIP/Postal Code
120-752
Country
Korea, Republic of
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Hui-Nam Pak, M.D., Ph.D.
Phone
82-2-2228-8459
Email
hnpak@yuhs.ac

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Computed Tomogram Myocardial Thickness Map Guided pulmOnary Vein iSolaTion vs. Empirical Pulmonary Vein Isolation in Cryoballoon Ablation for Paroxysmal Atrial Fibrillation (UTMOST AF II)

We'll reach out to this number within 24 hrs